News Archive

News Archive

Sarah Teichmann given Helmholtz International Fellow Award

teichman_faculty_9.jpg

Sarah Teichmann given Helmholtz International Fellow Award

Head of Cellular Genetics recognised with 20,000 Euros to further her research and an invitation to a research stay at Helmholtz Zentrum München (the German Research Centre for Environmental Health).

Dr Sarah Teichmann is one of five scientists to receive this year's Helmholtz International Fellow Award, and the only researcher from the medical sector to be honoured. The awards ceremony is scheduled for the 5 May 2017 at the Helmholtz Campus in Neuherberg near Munich.

Best treatment option written in cancer’s genetic script

topimage.jpg

Best treatment option written in cancer’s genetic script

Acute myeloid leukaemia study finds personalised therapy is possible

An international collaboration led by clinical researchers at the Wellcome Trust Sanger Institute has shown proof-of-concept that truly personalised therapy will be possible in the future for people with cancer. Details of how a knowledge bank could be used to find the best treatment option for people with acute myeloid leukaemia (AML) are published today (16 January 2017) in Nature Genetics.

New genes identified that regulate the spread of cancers

homepage_cancer_in_blood.jpg

New genes identified that regulate the spread of cancers

Study reveals Spns2 gene as a new drug target

Research led by the Wellcome Trust Sanger Institute has discovered a new biological target for drugs to reduce the spread of tumours in cancer patients. Published in Nature today (11 January 2017), the study with genetically modified mice found 23 genes that are involved in regulating the spread of cancers. The researchers showed that targeting one of these genes – Spns2 – led to a three-quarters reduction in tumour spread.

Largest ever genetic study of Primary Sclerosing Cholangitis reveals potential drug target

pscHome1.jpg

Largest ever genetic study of Primary Sclerosing Cholangitis reveals potential drug target

International collaboration finds associations with four regions of the genome in PSC patients

Primary Sclerosing Cholangitis (PSC) is a rare disease of the liver with no effective treatment. Researchers identify four regions of the genome associated with the disease, one of which is a potential drug target.

Cambridge Innovation Capital plc and IP Group plc announce the creation of Wellcome Trust Sanger Institute spin-out company, Microbiotica

storytop.jpg

Cambridge Innovation Capital plc and IP Group plc announce the creation of Wellcome Trust Sanger Institute spin-out company, Microbiotica

Based on ground-breaking research at the Wellcome Trust Sanger Institute into the role of the human microbiome in disease. Goal is to create the world’s leading company focused on microbiome biology and its use in medicine. Cambridge Innovation Capital and IP Group co-lead £8m funding round.

Microbiotica has been established to commercialise ground-breaking research, conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute, into the role of the human microbiome in health and disease and its application to medicine. The HMIL is led by Dr Trevor Lawley and collaborates with the Professor Gordon Dougan research group.

Online epidemic tracking tool embraces open data and collective intelligence to understand outbreaks

microreacthome.jpg

Online epidemic tracking tool embraces open data and collective intelligence to understand outbreaks

Researchers from the Wellcome Trust Sanger Institute and Imperial College London have developed Microreact, a free, real-time epidemic visualisation and tracking platform that has been used to monitor outbreaks of Ebola, Zika and antibiotic-resistant microbes

Microreact.org is a cloud-based system that combines the power of open data and the web, to provide real-time global data sharing and visualisation, allowing anyone to explore and examine outbreak information with unprecedented speed and detail. In collaboration with the Microbiology Society, any researcher around the world will be able to share their latest information about disease outbreaks.

Enhanced CRISPR lets scientists explore all steps of health and disease in every cell type

soptikohome.png

Enhanced CRISPR lets scientists explore all steps of health and disease in every cell type

Two new methods will allow researchers world-wide to rapidly and accurately explore the changing role of genes as the cells develop into tissues such as liver, skin or heart, and discover how this contributes to health and disease.

Wellcome Trust Sanger Institute and University of Cambridge researchers have created sOPTiKO, a more efficient and controllable CRISPR genome editing platform. Today (29 November), in the journal Development, they describe how the freely available single-step system works in every cell in the body and at every stage of development. This new approach will aid researchers in developmental biology, tissue regeneration and cancer.

Sanger spin-out secures $100 million

kymab.png

Sanger spin-out secures $100 million

Company founded on Institute technology goes from strength to strength.

Kymab is a company founded on genetic technologies developed at the Wellcome Trust Sanger Institute by Professor Allan Bradley. Its focus is discovering, developing and delivering new monoclonal antibody medicines to treat a variety of diseases.

River blindness worm’s genome reveals unique fatal flaws

onchocerciasis.jpg

River blindness worm’s genome reveals unique fatal flaws

In Nature Microbiology, Wellcome Trust Sanger Institute researchers revealed the whole genome of Onchocerca volvulus, and within it key differences to its evolutionary partner in crime

River blindness is a common chronic infectious neglected disease that blights many communities near water in remote areas of the Amazon basin in South America and in Africa. It is caused by the worm Onchocerca volvulus, whose larvae migrate through the body, including into the eyes of infected people, making them blind. The parasite is a major socioeconomic issue in the villages and families it affects because sufferers are no longer able to work. In addition other family members, often children, have to give up their studies or work to care for them, further depriving the family of income or future development.

Prime Minister opened £42M Biodata Innovation Centre and new Sequencing Facility

bicandbob.jpg

Prime Minister opened £42M Biodata Innovation Centre and new Sequencing Facility

The UK Prime Minister Rt Hon Theresa May today (21 November) joined key stakeholders from across the life sciences sector to open the Wellcome Trust Sanger Institute’s new Bridget Ogilvie Building and the Biodata Innovation Centre at the Wellcome Genome Campus in Cambridge.

Together these new buildings will house one of the world’s most advanced gene sequencing facilities and a unique innovation space for global genomics and biodata businesses. These buildings will be home to a powerful collaboration between academia, businesses large and small, charities and Government.

Pages